Sanofi Sees Unusually High Options Volume (SNY)
Sanofi (NYSE:SNY) saw some unusual options trading activity on Wednesday. Investors purchased 16,245 call options on the stock. This is an increase of approximately 1,652% compared to the typical volume of 927 call options.
Several large investors have recently modified their holdings of SNY. Harbour Capital Advisors LLC purchased a new stake in shares of Sanofi during the first quarter worth approximately $113,000. Nelson Van Denburg & Campbell Wealth Management Group LLC increased its stake in shares of Sanofi by 6,188.3% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 3,773 shares of the company’s stock worth $171,000 after buying an additional 3,713 shares during the period. Proficio Capital Partners LLC increased its stake in shares of Sanofi by 95.8% in the first quarter. Proficio Capital Partners LLC now owns 4,265 shares of the company’s stock worth $210,000 after buying an additional 2,087 shares during the period. Huntington National Bank increased its stake in shares of Sanofi by 3.4% in the first quarter. Huntington National Bank now owns 4,455 shares of the company’s stock worth $202,000 after buying an additional 147 shares during the period. Finally, BLB&B Advisors LLC purchased a new stake in shares of Sanofi during the first quarter worth approximately $202,000. Institutional investors and hedge funds own 9.84% of the company’s stock.
SNY has been the subject of several research reports. TheStreet raised shares of Sanofi from a “c+” rating to a “b-” rating in a research note on Monday, April 24th. Argus initiated coverage on shares of Sanofi in a research note on Thursday, April 6th. They set a “buy” rating and a $50.00 price objective for the company. Zacks Investment Research raised shares of Sanofi from a “hold” rating to a “buy” rating and set a $50.00 price objective for the company in a research note on Tuesday, April 11th. BidaskClub raised shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Finally, Berenberg Bank cut shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, May 11th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $67.67.
Shares of Sanofi (NYSE:SNY) opened at 48.18 on Friday. The stock has a 50 day moving average of $48.89 and a 200 day moving average of $44.55. Sanofi has a 1-year low of $36.81 and a 1-year high of $50.24. The stock has a market cap of $121.68 billion, a PE ratio of 11.65 and a beta of 0.89.
Sanofi (NYSE:SNY) last announced its earnings results on Friday, April 28th. The company reported $0.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.03. The company had revenue of $8.65 billion during the quarter, compared to analysts’ expectations of $8.40 billion. Sanofi had a net margin of 26.55% and a return on equity of 25.89%. The company’s revenue was up 1.2% on a year-over-year basis. Equities research analysts forecast that Sanofi will post $3.15 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/07/15/sanofi-sees-unusually-high-options-volume-sny.html.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.